Vaccine Transparency Act of 2021

Bill: 117-hr-1473
Sponsor: full_name: Rep. Steube, W. Gregory [R-FL-17]
Introduced: 2021-03-01
Policy area: Health
Subjects: Cardiovascular and respiratory health

Congressional oversight

Emergency medical services and trauma care

Health information and medical records

Immunology and vaccination

Infectious and parasitic diseases
Latest action: action_date: 2021-03-02
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2021-03-01
action_desc: Introduced in House
text: <p><strong>Vaccine Transparency Act of 2021</strong></p> <p>This bill requires the Food and Drug Administration and the Centers for Disease Control and Prevention to periodically report to Congress on the serious adverse events in connection with a COVID-19 (i.e., coronavirus disease 2019) vaccine that have been reported to either agency.</p>

tv_txt: I 117th CONGRESS 1st Session H. R. 1473 IN THE HOUSE OF REPRESENTATIVES March 1, 2021 Mr. Steube introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To require the Commissioner of Food and Drugs and the Director of the Centers for Disease Control and Prevention to report to Congress all serious adverse events that are reported to such agencies in connection with administration of a COVID–19 vaccine, and for other purposes.

1. Short title This Act may be cited as the Vaccine Transparency Act of 2021 . 2. Reports to Congress on serious adverse events in connection with COVID–19 vaccines (a) In general Not later than 60 days after the date of enactment of this Act, and every 60 days thereafter, the Commissioner of Food and Drugs and the Director of the Centers for Disease Control and Prevention, acting jointly, shall submit a report to the Congress on all serious adverse events that are reported— (1) to either agency pursuant to the Vaccine Adverse Event Reporting System or otherwise during the period covered by the report; and (2) in connection with a COVID–19 vaccine. (b) Initial report The reporting period of the initial report under subsection (a) shall begin on the date when the Commissioner of Food and Drugs first authorized emergency use of a COVID–19 vaccine under section 564 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bbb–3 ).